Taminadenant

N/A

Report date: 2024/01/02 20:03:52
NME

Base Information

Drug NameTaminadenant
Drug Alias NameTaminadenantNIR-178PBF-509
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2a receptor antagonistsAdenosine receptor antagonistsAnti-PD-1
TargetsAdenosine receptorAdenosine A2a receptorProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursParkinson DiseaseProstatic Neoplasms, Castration-Resistant +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[19] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPalobiofarma Sl
China Registration ClassN/A

Develop Information

Active CompaniesPalobiofarma Sl
Inactive CompaniesNovartis Pharma Ag
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumoursParkinson DiseaseProstatic Neoplasms, Castration-Resistant +[13] 

Other Information

ATC CodeN/A
Related LinksN/A